\n
'.concat(e.i18n.t("search.voice.permission_title"),'
\n
').concat(e.i18n.t("search.voice.permission_text"),"
\n
FAQs
Is AMRN a good stock to buy now? ›
Amarin currently has an average brokerage recommendation (ABR) of 4.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms.
What is the future of AMRN stock? ›AMRN Stock 12 Month Forecast
Based on 2 Wall Street analysts offering 12 month price targets for Amarin in the last 3 months. The average price target is $1.00 with a high forecast of $1.00 and a low forecast of $1.00. The average price target represents a 63.93% change from the last price of $0.61.
Stock Price Target AMRN
| High | $1.00 |
|---|---|
| Median | $1.00 |
| Low | $1.00 |
| Average | $1.00 |
| Current Price | $0.63 |
$1.02 ↑64.25% Estimated share price by August 26, 2025.
Why is Amarin stock so low? ›However, revenues declined 16% from the year-ago quarter's levels, owing to lower product revenues. Despite the better-than-expected results, shares of Amarin were down 12.9% on Jul 31. Year to date, the stock has plunged 21.6% compared with the industry's decline of 0.1%.
Who are the largest shareholders of Amarin? ›Largest shareholders include Sarissa Capital Management LP, Kynam Capital Management, LP, DG Capital Management, LLC, Eversept Partners, LP, Two Sigma Investments, Lp, Two Sigma Advisers, Lp, Morgan Stanley, SCP Investment, LP, Longitude (Cayman) Ltd., and Price Jennifer C. .
What drugs does Amarin make? ›VASCEPA is a prescription medicine used:
along with certain medicines (statins) to reduce the risk of heart attack, stroke and certain types of heart issues requiring hospitalization in adults with heart (cardiovascular) disease, or diabetes and 2 or more additional risk factors for heart disease.
Historical dividend payout and yield for Amarin (AMRN) since 1971. The current TTM dividend payout for Amarin (AMRN) as of September 06, 2024 is $0.00. The current dividend yield for Amarin as of September 06, 2024 is 0.00%.
Who owns AMRN stock? ›The ownership structure of Amarin (AMRN) stock is a mix of institutional, retail and individual investors. Approximately 15.70% of the company's stock is owned by Institutional Investors, 19.76% is owned by Insiders and 64.55% is owned by Public Companies and Individual Investors.
Who are Amarin competitors? ›Amarin's competitors
- Amarin.
- Horizon Therapeutics.
- Afimmune.
- Matinas BioPharma.
- Micelle BioPharma.
- Acasti Pharma.
What is target projected price? ›
What is Target's price target? The average price target for Target is $173.58. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
What is the target price? ›A price target is a price at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst raises their price target for a stock, they generally expect the stock price to rise.
What is the peri stock forecast for 2025? ›According to analysts, PERI price target is 9.33 USD with a max estimate of 10.00 USD and a min estimate of 9.00 USD.
What is the future of BioNano? ›BNGO Stock 12 Month Forecast
Based on 4 Wall Street analysts offering 12 month price targets for BioNano Genomics in the last 3 months. The average price target is $2.73 with a high forecast of $5.20 and a low forecast of $1.00. The average price target represents a 515.84% change from the last price of $0.44.
Highlights and Key Points: Visa Stock Forecast 2024–2030
Experts predict the average price at the end of 2024 to be around $285, with a potential maximum of $330 and a minimum of $273. The 2025 forecast suggests that Visa's stock price could reach $379 per share.
BioNano Genomics Inc's analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
Is Novartis a good company to invest in? ›Novartis Ag has a consensus rating of Hold which is based on 1 buy ratings, 5 hold ratings and 0 sell ratings. The average price target for Novartis Ag is $116.90. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
What is the dividend yield of AMRN? ›The current dividend yield for Amarin as of August 26, 2024 is 0.00%.
Is Titan Medical a good stock to buy? ›Overall, Titan Medical Inc stock has a Value Grade of D, Growth Grade of D, Momentum Grade of F .